You are here

  • Home
  • Archive
  • Volume 5, Issue 1
  • High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute

Article info

Article menu

Download PDFPDF

Research Article
High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute

Authors

  • Diwakar Davar University of Pittsburgh Cancer Institute and University of Pittsburgh Medical Center Pittsburgh PA USA Division of Hematology-OncologyUniversity of Pittsburgh Medical Center 5117 Centre Avenue 15232 Pittsburgh PA USA PubMed articlesGoogle scholar articles
  • Fei Ding Department of BiostatisticsUniversity of Pittsburgh and University of Pittsburgh Medical Center Pittsburgh PA USA PubMed articlesGoogle scholar articles
  • Melissa Saul Clinical Research InformaticsUniversity of Pittsburgh and University of Pittsburgh Medical Center Pittsburgh PA USA PubMed articlesGoogle scholar articles
  • Cindy Sander University of Pittsburgh Cancer Institute and University of Pittsburgh Medical Center Pittsburgh PA USA PubMed articlesGoogle scholar articles
  • Ahmad A. Tarhini Clinical and Translational ScienceUniversity of Pittsburgh Cancer Institute and University of Pittsburgh Medical Center Pittsburgh PA USA PubMed articlesGoogle scholar articles
  • John M. Kirkwood Dermatology, and Clinical and Translational ScienceUniversity of Pittsburgh Cancer Institute and University of Pittsburgh Medical Center Pittsburgh PA USA PubMed articlesGoogle scholar articles
  • Hussein A. Tawbi Department of Melanoma Medical Oncology, Division of Cancer MedicineThe University of Texas MD Anderson Cancer Center Houston TX USA PubMed articlesGoogle scholar articles
  1. ↵a 412-623-2467 davard{at}upmc.edu
  2. ↵b fed11{at}pitt.edu
  3. ↵c mis18{at}pitt.edu
  4. ↵d sanderca{at}upmc.edu
  5. ↵e tarhiniaa{at}upmc.edu
  6. ↵f kirkwoodjm{at}upmc.edu
  7. ↵g HTawbi{at}mdanderson.org
View Full Text

Citation

Davar D, Ding F, Saul M, et al
High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute
Journal for ImmunoTherapy of Cancer 2017;5:74. doi: 10.1186/s40425-017-0279-5

Publication history

  • Received June 7, 2017
  • Accepted August 29, 2017
  • First published September 19, 2017.
Online issue publication 
February 09, 2021

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© The Author(s). Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.